SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of November 2015
Commission File Number: 001-11960
2 Kingdom Street, London W2 6BD
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F __
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes __ No X
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
AstraZeneca PLC year-to-date and Q3 Results 2015
Tomorrow, Thursday, 5th November 2015, AstraZeneca PLC will release year-to-date and Q3 results for 2015 at 07:00 GMT.
An analyst presentation of the year to date and Q3 results for 2015 will take place at 12:00 GMT and will be accessible by a choice of two routes:
The presentation will be available to download on the AstraZeneca Investor Relations website http://www.astrazeneca.com/investors two hours before the analyst presentation begins.
Teleconference with Q&A. Dial in numbers:
UK (freephone): 0800 694 2370
International: +44 (0) 1452 557 749
Sweden (freephone): 0200 883 079
US (freephone): 866 977 7645
Conference ID: 75218823
Details of the teleconference and webcast replay facilities are available on the Investor Relations section of the AstraZeneca website http://www.astrazeneca.com/investors.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: 04 November 2015
By: /s/ Adrian Kemp
Name: Adrian Kemp
Title: Company Secretary